Downloaded from jcp.bmj.com on July 22, 2014 - Published by group.bmj.com
JCP Online First, published on July 22, 2014 as 10.1136/jclinpath-2014-202320 Original article
p-mTOR expression is associated with better prognosis in luminal breast carcinoma Francisco Beca,1,2,3 Rosario Andre,4,5 Duarte Saraiva Martins,6 Tiago Bilhim,7 Diana Martins,2 Fernando Schmitt2,8,9 ▸ Additional material is published online only. To view please visit the journal online (http://dx.doi.org/10.1136/ jclinpath-2014-202320). For numbered affiliations see end of article. Correspondence to Dr Fernando Schmitt, Faculty of Medicine, Department of Laboratory Medicine & Pathobiology, University of Toronto, University Health Network, Toronto General Hospital, 200 Elizabeth Street, 11E-215B, Toronto, Ontario, Canada M5G 2C4;
[email protected] Received 26 March 2014 Revised 3 July 2014 Accepted 4 July 2014
ABSTRACT Aims Despite considerable interest in the PI3K/AKT/ mTOR pathway in breast carcinomas (BC), published data reports contradictory results regarding the association of phosphorylated mammalian target of Rapamycin ( p-mTOR) expression with clinico-pathological features and prognosis in BC. Here, we evaluate the main clinico-pathological associations with p-mTOR expression in BC, with focus on the different molecular subtypes. Methods In this retrospective study, 331 BC patients were included in final analysis. Outcome measures included disease-free survival (DFS) and overall survival (OS) times. Baseline data and outcome measures were compared between immunohistochemical p-mTOR expressing and non-expressing BCs. Subgroup analysis was performed to assess the effect of p-mTOR expression in the outcome for each BC molecular subtype. Results 43.8% of the tumours were positive for pmTOR, with a significant correlation between p-mTOR expression with smaller (
